Zynerba Pharmaceuticals’ lead drug candidate is designed to bring the therapeutic effect of cannabinoids without also causing euphoric effects. The synthetic cannabinoid in a topical gel formulation includes none of the psychoactive compounds from the cannabis plant.
The European Commission approved GW Pharma's Epidyolex as a treatment for seizures in two rare and severe forms of epilepsy. The drug won FDA approval last year.
The layout of your phlebotomy station can significantly impact efficiency. A well-thought-out setup ensures that every tool is within reach, minimizing unnecessary movement and reducing patient wait times.
The drug showed positive results in a 210-patient study in patients experiencing treatment-resistant seizures from tuberous sclerosis complex, a rare form of epilepsy.
The FDA approved the cannabis-based drug for treating seizures in two severe forms of epilepsy.
From eye drops for glaucoma to chewing gum for irritable bowel syndrome, derivatives of cannabis are making their way into FDA trials in pursuit of a biotech/pharma market projected to reach $20 billion by 2020.